Technology · Biotechnology R&D expenditure
In 2026, China's reported biotechnology R&D expenditure was 30 B $, ranking 1 out of 197 nations. This figure, however, is misleading: China is among the top three global investors in biotech, second only to the United States. Massive funding flows into genomics, gene editing, and biopharmaceuticals, particularly in hubs like Shanghai, Shenzhen, and Beijing. The zero value likely stems from reporting methodologies that exclude state-led R&D programs from market-based statistics.
Data for 2026 · unit: $
Position
#1 / 197
China world ranking
Country position on the scale from last to first place for this indicator.
CN
#1
#197#1
Trend
Change over time
Change in indicator over the available period.
50 M
1990
500 M
2000
5 B
2010
25 B
2020
30 B
2025
30 B
2026
Values — $
Comparison
Top countries by Biotechnology R&D expenditure
Where China stands in the world ranking.
1
CNChina
30 B
1
USUSA
30 B
3
JPJapan
25 B
4
MXMexico
1 B
4
BRBrazil
1 B
6
CACanada
800 M
6
DEGermany
800 M
8
ESSpain
650 M
Full world rankingarrow_forward
People also search for
Other pages of the reference by this indicator.
Frequently asked questions
Biotechnology R&D expenditure in China — how much?
Based on 2026 data — 30 B $. This is rank #1 out of 197 countries.
What is China's rank by Biotechnology R&D expenditure?
China ranks #1 out of 197 countries in the world ranking by «Biotechnology R&D expenditure».
How has Biotechnology R&D expenditure changed in China?
Over the available period the indicator changed from 50 M to 30 B $.